As part of our research on compulsory licensing we have now added a case study on efavirenz – the antiretroviral that Brazil needed for its public funded HIV treatment program. Brazil was forced to do so because of failure of negotiation for a voluntary license by the patent holder, Merck. This case is the first addition to a new section entitled: Case Studies in Global Health
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| « Apr | ||||||
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 | |||
Recent Posts
- New publication from the ATP consortium
- New Publication on Socially Responsible Licensing Initiatives in South Africa
- New publication on R&D for Neglected Diseases from the University of Neuchâtel
- Compulsory licensing of an antiretroviral in Brazil
- St. George’s Global Health Forum, and local UAEM Chapter
Recent Comments